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A Perspective on the Use of NB-UVB
Phototherapy vs. PUVA
Photochemotherapy
Sally H. Ibbotson*
Photobiology Unit, Dermatology Department, Ninewells Hospital, University of Dundee School of Medicine, Dundee,
United Kingdom
Narrowband UVB (NB-UVB) phototherapy and psoralen-UVA (PUVA)
photochemotherapy are widely used phototherapeutic modalities for a range of
skin diseases. The main indication for NB-UVB and PUVA therapies is psoriasis, and
other key diagnoses include atopic eczema, vitiligo, cutaneous T-cell lymphoma (CTCL),
and the photodermatoses. The decision on choice of phototherapy is important and
NB-UVB is usually the primary choice. NB-UVB phototherapy is a safe and effective
therapy which is usually considered when topical agents have failed. PUVA requires
prior psoralen sensitization but remains a highly effective mainstay therapy, often used
when NB-UVB fails, there is rapid relapse following NB-UVB or in specific indications,
such as pustular or erythrodermic psoriasis. This review will provide a perspective on
the main indications for use of NB-UVB and PUVA therapies and provide comparative
information on these important dermatological treatments.
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INTRODUCTION
Narrowband UVB (NB-UVB) phototherapy and psoralen-UVA (PUVA) photochemotherapy
are widely used light-based treatments for a range of diverse skin diseases and can be highly
effective, well-tolerated, safe, cost-saving, and reduce the need for topical therapies (1–6). The
main indication for NB-UVB or PUVA is psoriasis (7) but other mainstay indications include
atopic dermatitis or dermatitis of other cause, vitiligo, cutaneous T-cell lymphoma (CTCL), and
a range of other conditions, including the photodermatoses, pityriasis rubra pilaris, urticaria,
aquagenic pruritus, urticaria pigmentosum, pityriasis lichenoides, lichen planus, granuloma
annulare, alopecia areata, and graft vs. host disease (2, 3, 5, 6) (Table 1).
If topical treatments fail to establish adequate control of disease then a light-based therapy would
be a next appropriate treatment choice and in most instances NB-UVB would be selected as the
primary phototherapeutic option. However, in certain diseases such as erythrodermic or pustular
psoriasis, pityriasis rubra pilaris, or plaque stage CTCL, PUVA would be the desired option (5).
I am going to provide my opinion and perspective on the relative uses of NB-UVB and PUVA
for a range of diseases, with particular emphasis on psoriasis as the predominant indication for
a UV-light based therapy and with briefer mention on the salient points relative to the use of
NB-UVB and PUVA in other conditions. I am restricting my review to NB-UVB and PUVA and
am not including BB-UVB or UVA1 phototherapies.
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TABLE 1 | Key indications for NB-UVB or PUVA.
Psoriasis
Pustular or erythrodermic*
Eczema – atopic or other type
Vitiligo
Cutaneous T-cell lymphoma
Patch
Plaque*
Photodermatoses
Polymorphic light eruption, actinic prurigo, solar urticaria, hydroa vacciniforme,
erythropoietic protoporphyria
Chronic actinic dermatitis*
Urticaria
Urticaria pigmentosa
Aquagenic pruritus
Mastocytoses
Generalised pruritus
For example secondary to cholestasis or uraemia
Pityriasis lichenoides chronica
Lichen planus
Granuloma annulare
Graft vs. host disease
Alopecia areata*
Pityriasis rubra pilaris*
Hand & foot eczema*
Palmoplantar pustulosis*
*Consider PUVA in preference to UVB.
BACKGROUND
UVB was introduced into increasingly widespread and routine
use following developmental work in the 1980s (8–11). NB-
UVB phototherapy reduces the need for topical therapies (1)
and is a cost effective (12) and safe treatment, which involves
repeated controlled delivery of the narrowband region of the
UVB spectrum centered on 311 nm (4, 6). The main acute
adverse effects of NB-UVB are erythema and induction of
photosensitivity diseases, such as polymorphic light eruption
(PLE). However, although the risk of erythemal episodes may
be increased by concomitant phototoxic drugs (13, 14), this
can be minimized by undertaking a baseline minimal erythema
dose (MED) and establishing treatment protocols based on
an individual’s MED (15). This also allows any unsuspected
abnormal photosensitivity diseases to be detected, in particular
solar urticaria or chronic actinic dermatitis (CAD). Induction
of PLE may occur during a treatment course but generally
can be accommodated via dose adjustments and judicious use
of topical corticosteroid, without the need to stop NB-UVB
(16). Other uncommon side-effects, such as psoriatic lesional
blistering, occasionally occur but generally treatment is very well-
tolerated (17, 18). Importantly, NB-UVB can be safely used in
children and in pregnancy and long-term studies to date do not
indicate a significantly increased risk of skin cancer over an age-
and sex-matched control population who have not received UVB
phototherapy (19–21).
PUVA photochemotherapy is delivered using psoralen
administration via either systemic (8-methoxypsoralen or 5-
methoxypsoralen) or topical (usually now 8-methoxypsoralen as
bath, soak, gel, cream, or lotion) routes (5). The mechanism
of action of PUVA is quite distinct from that of UVB or of
UVA alone, with PUVA inducing a delayed erythemal reaction
peaking around 96 h after irradiation of psoralen-sensitized skin
(22–27). This contrasts with the peak time for development of
erythema after NB-UVB exposure of 12–24 h (28). Treatment
is thus logistically slightly more of a challenge as psoralen
sensitization is required. With systemic PUVA, appropriate skin
and eye protection must be used for 24 h after psoralen ingestion.
Oral 8-methoxypsoralen may cause some gastrointestinal upset,
although switching to 5-methoxypsoralen minimizes this adverse
effect and of course this is not an issue with topical PUVA.
However, PUVA treatment can be highly effective and very
safely administered in any Dermatology Department with a
significantly sized Phototherapy Unit.
With the exception of less common adverse effects such as
PUVA pain, treatment is otherwise usually well-tolerated (5).
Undoubtedly, there is a longer term risk of skin carcinogenesis
with high numbers of PUVA exposures (19, 29–37), but the risks
can be minimized by vigilance, limitation of lifetime numbers of
PUVA exposures, and avoidance of the use of maintenance PUVA
where possible. As with all therapeutic approaches, benefit, and
risk must be evaluated and it is important that PUVA is kept
firmly in the range of treatment options as it can be highly
effective, resulting in clearance, and marked improvement in
quality of life for patients with psoriasis and a variety of other
diseases.
It is essential that adequate governance is ensured for the
safe delivery of both NB-UVB and PUVA therapies. In Scotland
we have established the National Managed Clinical Network
for phototherapy (Photonet; www.photonet.scot.nhs.uk), which
employs a central database (Photosys), enabling standardization
of treatment protocols, recording of treatment parameters, and
outcomes and facilitating linkage studies to ascertain longer-
term risks of treatment, notably skin cancer risk (20, 21).
This has been an invaluable asset to allow standardization of
phototherapy services in Scotland and delivery of effective and
safe treatment for patients. This approach is now being adopted
in England and has important roles in delivery of optimized safe
care.
PSORIASIS
The main indication for any light-based therapy is psoriasis, and
for the reasons highlighted in terms of practicalities and ease of
treatment and its safety and potential for use in children and
pregnancy, NB-UVB phototherapy would usually be the light-
based therapy of choice, with high clearance rates achieved for
chronic plaque psoriasis (6, 38–40).
In an initial controlled comparative half-body study in 10
patients with widespread psoriasis, no significant difference
in efficacy was seen between twice weekly NB-UVB or
systemic PUVA (41) and this observation was also reported
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in a separate intra-individual open non-randomized controlled
paired comparison study of three times weekly NB-UVB and
PUVA, with no significant difference in efficacy seen between
the treatment arms. However, there was a trend to superior
efficacy with PUVA and this was particularly evident for patients
with a higher baseline PASI score (42), possibly suggestive of a
role for PUVA in more severe psoriasis or relapsing psoriasis,
although given the convenience of NB-UVB this would generally
be the preferred initial approach. In a separate inter-individual
study of 100 patients with psoriasis, twice weekly PUVA was
superior in efficacy to twice-weekly NB-UVB, with 35% of
patients still being clear at 6 months after completion of PUVA,
compared with only 12% after NB-UVB (43). These findings
are supported by those of a separate study in which 93 patients
with chronic plaque psoriasis were randomized to receive either
twice-weekly oral PUVA or twice-weekly NB-UVB, resulting in
84% achieving clearance with PUVA compared with significantly
lower clearance rates (65%) with NB-UVB and shorter remission,
as 6 months after treatment 68% of those treated with PUVA
were still in remission, compared with only 35% of patients
treated with NB-UVB (44). Of note, lower clearance rates were
achieved in patients of skin phototype V and VI, with only 24%
achieving clearance, although baseline psoriasis severity was not a
determinant of response in this study (44). However, high efficacy
rates have been reported in patients of higher skin phototypes (IV
and V), with 81–82% of patients showing marked improvement
with three times weekly 8-MOP PUVA or NB-UVB and no
difference between the two treatment regimens, indicating that
phototherapy or photochemotherapy should certainly still be
considered for patients with higher skin phototypes (45).
Given that three-times weekly NB-UVB results in faster
more efficient clearance of psoriasis than twice-weekly treatment
(46), comparison of twice weekly PUVA with a twice-weekly
NB-UVB regimen is likely to be including a sub-optimal NB-
UVB treatment arm. Indeed, in an intra-individual randomized
controlled study of three times weekly NB-UVB with twice-
weekly TMP bath PUVA, NB-UVB was of superior efficacy and
also resulted in more rapid response of psoriasis, with 75%
clearance compared with 54% with PUVA (40). Additionally, in
a randomized intra-individual half-side study in patients with
chronic plaque psoriasis, comparing three times weekly TMP
bath PUVA and three times weekly NB-UVB, again NB-UVB was
of superior efficacy compared with TMP bath PUVA, although
all patients relapsed within 4 months of follow-up (47). In
contrast, Salem et al., undertook a randomized controlled trial
in 34 patients, comparing 8-MOP bath PUVA three times a week
with three times weekly NB-UVB and greater reduction in PASI
score was seen with PUVA than NB-UVB, along with greater
reduction in peripheral CD4+ T Cells, indicative of possible
systemic effects (48). Furthermore, Markham et al., undertook
an open randomized inter-individual comparative study of twice-
weekly oral 8-MOP PUVA with three times weekly NB-UVB for
chronic plaque psoriasis and showed equivalent efficacy in terms
of time to clearance and period of remission (49).
Thus, trying to make sensible conclusions from this diverse
range of study findings, given the ease, convenience, and safety
of treatment and the study evidence, NB-UVB should usually
be considered as the first phototherapeutic option for patients
with chronic plaque psoriasis, with PUVA used when NB-
UVB is not effective or there is rapid relapse once NB-UVB
is discontinued (39). A lower threshold for considering PUVA
is reasonable if psoriasis is particularly thick and/or extensive
at baseline, including erythrodermic and pustular psoriasis (50)
or the patient is of higher skin phototype. In addition, 8-MOP
bath or oral PUVA may be preferable to TMP bath PUVA, as
although no head to head comparison has been undertaken,
lower response rates are reported for those studies using TMP
bath PUVA rather than 8-MOP (40, 47–49). Erythemogenic
doses of PUVA are not a pre-requisite for clearance (51) and
maintenance PUVA or NB-UVB for psoriasis should generally
be avoided (52). Failure to respond to NB-UVB does not equate
to prediction of a lack of response to PUVA and the latter
should be considered for those who fail to do well with NB-UVB.
For children, NB-UVB phototherapy is preferred and PUVA is
relatively contraindicated, although this is not an absolute rule,
but given the concerns about long-term safety, PUVA would not
be the first line choice.
ECZEMA
Whilst any light-based treatment approach is less straightforward
for eczema than psoriasis, not least for the reason of flaring of
eczema in the early stages of treatment mainly due to the heat
load of therapy, both NB-UVB and PUVA can be highly effective
for the treatment of atopic eczema and other forms of eczema
(5, 6). However, the evidence-base is relatively weak and there are
no prospective studies comparing head-to-head systemic PUVA
with NB-UVB (53). Systemic 5-MOP PUVA was shown to be
superior to medium dose UVA1 for atopic eczema in an intra-
individual randomized controlled comparison study (54). Bath
PUVA can also be highly effective for atopic eczema (55). Bath
PUVA using 8-MOP was compared with NB-UVB in a small
half-side comparison study, showing that both were effective for
severe atopic eczema without a significant difference between the
two therapies (56). Thus, NB-UVB would usually be the first line
of choice for atopic eczema, given the ease of administration,
safety, and potential for use in children (57). Given the response
of atopic eczema to several types of light-based therapy and
if NB-UVB phototherapy fails or there is early relapse after
discontinuation of treatment, then the options of either PUVA
or UVA1 exist, although given the lack of evidence of superiority
of UVA1, the latter would likely only be considered if PUVA was
contraindicated. Indeed, a combination of NB-UVB and UVA or
UVA1 could be considered for some patients, although whether
this is advantageous compared with UVB alone is unclear and
this needs further study (58).
VITILIGO
For the treatment of vitiligo, NB-UVB has been shown to
be superior to PUVA with respect to rates of repigmentation,
particularly for unstable extensive vitiligo, and in achieving more
cosmetically acceptable even repigmentation (59–63). Thus,
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NB-UVB would be the phototherapy of choice for vitiligo,
although PUVA may be considered in certain cases, particularly
if there is lack of response to NB-UVB.
CUTANEOUS T-CELL LYMPHOMA
Whilst there are no direct head-to-head controlled trials of NB-
UVB and PUVA for early stage CTCL, both have been shown to
be effective for this stage of disease (5, 64). In one retrospective
study 81% of patients with early stage CTCL achieved complete
remission with NB-UVB, compared with 71% with PUVA
(n = 56) (65). This observation has also been supported by two
other studies showing equivalent efficacy for NB-UVB and PUVA
in achieving remission of early stage CTCL (66, 67) and thus
NB-UVB should be the phototherapy of choice for early patch
stage CTCL disease, with complete remission in approximately
three quarters of patients being achievable, although duration of
remission has not been thoroughly evaluated and relapse may
occur within 6 months (68). It is unclear whether phototherapy
has any impact on limiting natural disease progression. Based
on one study it was suggested that tumor stage CTCL was
slower to develop and overall survival was improved in those
who had previously received phototherapy, although given the
retrospective nature of the study these data must not be obver-
interpreted (69). For thicker plaque stage CTCL, the increased
depth of penetration of PUVA is desirable and NB-UVB would
not be indicated, whereas PUVA would be the phototherapeutic
modality of choice (5). For tumor stage disease, PUVA as
monotherapy would not suffice and combination therapy is likely
to be required. Maintenance PUVA should generally be avoided,
but occasionally is justified for maintenance use in CTCL (5,
70). However, other adjunctive agents should be considered and
combination with retinoids, rexinoids, or interferon may be
required or the use of radiotherapy for localized tumor stage
disease or total skin electron beam treatment for more extensive
involvement (5). Photopheresis may of course be required for
Sezary syndrome (71, 72). Thus, in summary NB-UVB for early
stage disease and PUVA for plaque stage disease as monotherapy
or in combination therapy for more advanced disease should be
considered as mainstays in management (5, 64, 73)
THE PHOTODERMATOSES
There is a relative lack of randomized controlled trial evidence
investigating the use of NB-UVB and PUVA for the abnormal
photosensitivity conditions. However, for desensitization of PLE,
comparative studies show equivalent efficacy for NB-UVB and
PUVA (16). As regular annual desensitization courses may be
required from a relatively young age, NB-UVB is preferred for
PLE as the phototherapy of choice, although PUVA should be
considered for treatment failures and when reported its use
may be for more severe PLE (74, 75). Induction of PLE during
treatment is common and to be expected but does not usually
require early termination of the desensitization course and can
usually be accommodated with reduction of dose increments and
topical corticosteroid use during the treatment course (16, 76).
With the other less common photodermatoses, desensitization
phototherapies with either NB-UVB or PUVAmay be considered
and appropriate but will depend on the action spectrum for
induction of abnormal photosensitivity and thus which light-
based treatment approach can be tolerated. In general, these
patients should be investigated and managed through a specialist
photodermatology unit as there may be additional needs, such
as inpatient requirements for suppression and light-protected
care and advice regarding subsequent natural sunlight top up
exposure. In CAD, the action spectrum for induction of abnormal
photosensitivity is usually maximal in the UVB region and
therefore NB-UVB phototherapy cannot often be tolerated. In
this setting PUVA may need to be considered, sometimes in
combination with topical superpotent or systemic corticosteroids
in order to reduce the risk of disease flare, particularly in the early
stages of treatment (77, 78).
NB-UVB and PUVA may also be useful therapeutic
approaches for the other photodermatoses, such as erythropoietic
protoporphyria, hydroa vacciniforme, actinic prurigo, and
idiopathic solar urticaria (79). Indeed, in solar urticaria the
action spectrum for induction of urticaria is usually in the UVA
and visible parts of the spectrum and NB-UVB responses are
typically normal, in which case NB-UVB desensitization can be
used successfully for desensitization, with UVA rush hardening
and/or PUVA considered if NB-UVB is not feasible or successful
(79–84).
It would generally also be advisable for patients with solar
urticaria to have anti-histamine cover whilst receiving a UV-
based therapy. In EPP, as photosensitivity is maximal in the
visible part of the spectrum, NB-UVB is usually well-tolerated
and can be highly effective and is the phototherapy of choice.
Whilst here is limited evidence to support the use of PUVA,
given that patients with EPPwill usually require annual treatment
courses from a young age, NB-UVB is advised and PUVA is rarely
justified (85–88). Similarly, whilst there is limited evidence to
support the use of NB-UVB and PUVA in actinic prurigo, again
given the young age and need for annual treatment, NB-UVB
is advised and PUVA rarely needed, although may occasionally
be required (79). Factors such as the age of the patient, risk
factors such as skin phototype and evidence of photodamage and
the action spectrum for induction of abnormal photosensitivity,
should always be taken into account in any decision regarding
NB-UVB or PUVA and for the photodermatoses, specialist advice
regarding timing of desensitization courses, risk of induction
of the condition by treatment and management of that, top-up
exposure requirements after treatment and the need for annual
treatment courses must be addressed in order to establish the
optimal approach for any given patient.
LOCALIZED HAND AND FOOT DISEASE
Hand and foot dermatoses are a mixed group of conditions,
which include hyperkeratotic eczema, psoriasis, psoriasiform
dermatitis, palmoplantar pustulosis. There is a lack of robust
evidence regarding the optimal management of these diseases,
including the role of NB-UVB and PUVA therapies and there is
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no reason to consider that one approach will suit all conditions.
Undoubtedly, NB-UVB and PUVA photochemotherapy may be
useful for localized hand and foot dermatoses (89). Although oral
PUVA and NB-UVB may both be effective for eczema of the
palms and soles, oral PUVA has been shown to be superior to
NB-UVB in two small studies from the same group, although
relapse rates were high following both treatments (5, 90, 91).
The depth of penetration of 8-MOP systemic PUVA may be
desirable for recalcitrant hand and foot dermatitis and other
uncontrolled studies have also shown high levels of efficacy with
oral PUVA for hand and foot eczema (5, 92, 93). In contrast,
topical PUVA has not been shown to be superior to placebo
or any other active treatment, despite uncontrolled studies, and
anecdotal observations that efficacy can be achieved and this
is an area requiring further research. Thus, for hand and foot
eczema, oral PUVA would be the light-based therapy of choice
(5). Psoriasis of the palms and soles has been even less well
evaluated and, whilst there is some evidence to support the use
of PUVA, either with oral or topical psoralens, the strength of
evidence is weak and further studies are required (5, 7, 94). For
palmoplantar pustulosis, again oral PUVA either as monotherapy
or combined with retinoids, may be highly effective (5, 95–97)
and the role of NB-UV is less clear as has not been evaluated.
OTHER INDICATIONS
There is evidence that NB-UVB and PUVA may be effective
for urticaria and indeed randomized controlled trial evidence
to show the superior efficacy of NB-UVB plus anti-histamine
compared with anti-histamine alone (98–100). More recently,
superiority of NB-UVB compared with PUVA has been
shown for urticaria (101), and thus NB-UVB should be
considered as a treatment option if antihistamines and other
pharmacological therapies fail and may provide useful disease
remission. A range of other conditions may be effectively
treated by NB-UVB and PUVA and include pityriasis lichenoides
(102), granuloma annulare (103, 104), urticaria pigmentosa
and cutaneous mastocytoses (105–107), aquagenic pruritus
(108–110), lichen planus (111–114), alopecia areata (115–
118), generalized pruritus, such as secondary to uraemia or
cholestasis (119, 120), and graft vs. host disease (2, 3, 5,
6) and these phototherapeutic modalities may be invaluable
treatment approaches for these otherwise difficult-to-treat groups
of diseases. For conditions such as pityriasis rubra pilaris, which
may be aggravated and flared by the use of NB-UVB, 8-MOP
systemic PUVA should be considered.
CONCLUSIONS
To summarize, NB-UVB phototherapy and PUVA
photochemotherapy are both invaluable treatments to have
available in any dermatology department and should be
prioritized, not only for psoriasis, but in a variety of other
inflammatory and proliferative skin diseases, including atopic
eczema. Treatment can be safely and easily administered and
is well tolerated with few adverse effects. Excellent disease
remission may be achieved, whilst sparing the use of other
potentially toxic drugs at a relatively early stage in a patient’s
journey. Head-to-head comparative monotherapy studies with
biologic therapies do not exist and are needed. Due to the relative
cost-efficacy of the phototherapies and the understanding of
their long-term safety profiles compared with the cost and less
lengthy follow-up for the biologics, these should be employed
prior to consideration of biologic treatments (1). As with any
therapy, standardization of optimized treatment regimens,
careful observation of treatments delivered and therapeutic
outcomes, adverse effects and long-term follow-up studies,
including determining any skin cancer risk, are essential. The
development of the National Managed Clinical Network for
Phototherapy has had a major impact on standardization,
safety, and vigilance in delivery of our phototherapy
practices in Scotland and has proved to be an invaluable
tool, enabling the place of NB-UVB, and PUVA therapies
to continue to be well-established in the treatment of skin
disease.
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